Piper Sandler upgrades Supernus Pharmaceuticals stock rating on Onapgo potential
PositiveFinancial Markets

Piper Sandler has upgraded the stock rating of Supernus Pharmaceuticals, highlighting the potential of its drug Onapgo. This upgrade is significant as it reflects growing confidence in the company's future prospects and the effectiveness of its product, which could lead to increased investor interest and potentially higher stock prices. Such developments are crucial in the competitive pharmaceutical market, where innovative treatments can make a substantial impact on a company's success.
— Curated by the World Pulse Now AI Editorial System